Consensus Collegium Pharmaceutical, Inc.

Stocks

COLL

US19459J1043

Pharmaceuticals

Real-time Estimate Cboe BZX 13:52:58 2026-10-23 EDT			5-day change	1st Jan Change
22.66 ^USD	-3.57%		-1.81%	-50.82%

10-19	Collegium Pharmaceutical Settles Nucynta Patent Litigation for $17 Million	MT
10-09	Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer Says	MT

Evolution of the Average Target: Collegium Pharmaceutical, Inc.

Evolution of the Target Price: Collegium Pharmaceutical, Inc.

Changes in Analyst Recommendations: Collegium Pharmaceutical, Inc.

063d16ef8daacb3fbc64b038fdf6ba1.fk7U4xPTKMEjuBHOnd5MS4UWhPkqmUsivghiMKsnAW4.JgaHgnC9G5Fr0CaH1JwdJrNg78BorQpu2z8VeOcXYyonNJOVIZUesHX-JQ~e9462d64181fc846912c71509deb16e4

Analysts' recommendations: Collegium Pharmaceutical, Inc.

10-09	Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer Says	MT
09-23	Collegium's Durable Cash Flow From Pain Portfolio Poised to Support Further Business Development, Oppenheimer Says	MT
09-23	Oppenheimer Initiates Collegium Pharmaceutical at Outperform With $50 Price Target	MT
09-09	Leerink Partners Initiates Coverage on Collegium Pharmaceutical With Outperform Rating, $45 Price Target	MT
09-09	Truist Cuts Price Target on Collegium Pharmaceutical to $49 From $58, Keeps Buy Rating	MT
02-10	Truist Adjusts Price Target on Collegium Pharmaceutical to $58 From $55, Maintains Buy Rating	MT
01-07	Truist Securities Adjusts Price Target on Collegium Pharmaceutical to $55 From $48, Maintains Buy Rating	MT
12-09	Barclays Initiates Collegium Pharmaceutical at Overweight With $58 Price Target	MT
11-07	Truist Raises Price Target on Collegium Pharmaceutical to $48 From $45, Keeps Buy Rating	MT
25-08-08	Truist Raises Price Target on Collegium Pharmaceutical to $45 From $42, Keeps Buy Rating	MT
25-08-07	Collegium Pharma Q2 revenue beats analyst expectations	RE
25-01-10	Needham Upgrades Collegium Pharmaceutical to Buy From Hold, Price Target is $46	MT
24-08-09	Truist Securities Adjusts Price Target on Collegium Pharmaceutical to $42 From $40, Maintains Buy Rating	MT
24-07-30	HC Wainwright Upgrades Collegium Pharmaceutical to Buy From Neutral, Price Target is $47	MT
24-06-07	Jefferies Upgrades Collegium Pharmaceutical to Buy From Hold, Adjusts Price Target to $44 From $41	MT
24-05-10	Needham Downgrades Collegium Pharmaceutical to Hold From Buy	MT
24-05-10	Piper Downgrades Collegium Pharmaceutical to Neutral From Overweight, Price Target at $39	MT
24-02-26	Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating	MT
24-02-26	Truist Adjusts Price Target on Collegium Pharmaceutical to $40 From $37, Maintains Buy Rating	MT
24-01-04	Truist Adjusts Collegium Pharmaceutical's Price Target to $37 From $31, Keeps Buy Rating	MT
24-01-04	Jefferies Downgrades Collegium Pharmaceutical to Hold From Buy, Raises Price Target to $37 From $30	MT
23-08-25	Needham Adjusts Price Target on Collegium Pharmaceutical to $36 From $35, Maintains Buy Rating	MT
23-05-02	Jefferies Assumes Collegium Pharmaceutical at Buy With $30 Price Target	MT
23-01-05	Needham Adjusts Price Target on Collegium Pharmaceutical to $35 From $34, Maintains Buy Rating	MT
22-11-04	Needham Adjusts Price Target on Collegium Pharmaceutical to $34 From $36, Maintains Buy Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	COLLEGIUM PHARMACEUTICAL, INC.					+108.51%
	ELI LILLY AND COMPANY					+1.9%
	JOHNSON & JOHNSON					+4.41%
	ABBVIE INC.					-0.14%
	ROCHE HOLDING AG					-1.64%
	MERCK & CO., INC.					+7.69%
	NOVARTIS AG					-4.18%
	ASTRAZENECA PLC					+21.09%
	AMGEN INC.					-11.31%
	GILEAD SCIENCES, INC.					+1.89%
	Average					+12.82%
	Weighted average by Cap.					+2.31%